POS1607 BIOLOGICS THERAPIES FOR PSORIASIS DECREASE FUTURE RISK FOR DEVELOPING PSORIATIC ARTHRITIS

BackgroundPsoriasis (PsO) is an inflammatory skin disorder with an estimated worldwide prevalence of 2–4% [1]. Psoriatic arthritis (PsA) is highly associated with higher severity of PsO, present in up to 30% of patients and 0.3–1.0% of the global population and PsA typically develops after PsO [1,2]...

Full description

Saved in:

Bibliographic Details
Published in:	Annals of the rheumatic diseases Vol. 82; no. Suppl 1; pp. 1148 - 1149
Main Authors:	Dotan, A., Ben-Shabat, N., Mcgonagle, D., Amital, H., Watad, A.
Format:	Journal Article
Language:	English
Published:	Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2023 Elsevier B.V Elsevier Limited
Subjects:	Antibiotics bDMARD Biological products Body mass index Diagnosis Disease-modifying drugs (DMARDs) Epidemiology Gender Health maintenance organizations HMOs HuR protein Immunotherapy Methotrexate Patients Phototherapy Population studies Psoriasis Psoriatic arthritis Scientific Abstracts Skin diseases Sulfasalazine Disease-modifying drugs (DMARDs) bDMARD Psoriatic arthritis
ISSN:	0003-4967, 1468-2060
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!